Contact Information: Contact: Investors NovaBay Pharmaceuticals, Inc. Thomas J. Paulson Chief Financial Officer 510-899-8809 tpaulson@novabaypharma.com Media Susan Thomas 510-899-8841 sthomas@novabaypharma.com
NovaBay Pharmaceuticals to Present at the 2010 BIO CEO & Investor Conference
| Source: NovaBay Pharmaceuticals
EMERYVILLE, CA--(Marketwire - February 4, 2010) - NovaBay Pharmaceuticals, Inc. (NYSE Amex : NBY ), a clinical stage biopharmaceutical company developing first-in-class,
anti-infective compounds in the treatment and prevention of
antibiotic-resistant infections, today announced that Ron Najafi, Ph.D.,
Chairman and Chief Executive Officer, will deliver a corporate presentation
at the 12th Annual BIO CEO & Investor Conference on Tuesday, Feb. 9 in New
York City.
Dr. Najafi's presentation will take place at 2:30 p.m. ET in the Duke of
Windsor room at the Waldorf Astoria. His presentation will provide a
corporate overview and highlight NovaBay's clinical progress in its
internal programs, as well as in its partnered programs with Alcon (NYSE : ACL ) and Galderma.
An audio of the presentation will be available on NovaBay's homepage at
www.novabaypharma.com.
About NovaBay
NovaBay Pharmaceuticals is a clinical stage biopharmaceutical company
focused on developing its proprietary and patented Aganocide® compounds,
which are novel, synthetic anti-infective product candidates with
equivalent activity to the active antimicrobial molecules generated within
white blood cells. NovaBay's Aganocides are being developed to treat and
prevent a wide range of infections without causing bacterial resistance.
NovaBay has internal development programs aimed at addressing hospital and
respiratory infections. The company has a license and research
collaboration agreement with Alcon, Inc. for use of its Aganocide compounds
to treat eye, ear and sinus infections as well as for contact lens care.
NovaBay has also entered into an agreement with Galderma S.A. to develop
and commercialize Aganocides in acne, impetigo and other dermatological
indications. For more information on NovaBay, visit: www.novabaypharma.com.